Influence of Decoction Duration of FDY2004 on Its Physicochemical Components and Antioxidant and Antiproliferative Activities

Lee, In-Hee; Lee, Ho-Sung; Kang, Kyung‐Won; Park, Sang‐In; Kwon, Tae-Wook; Moon, Seung-Joon; Lee, Chol Hee; Lee, Dae Yeon

doi:10.1177/1934578x20968437

Cited by 6 publications

(12 citation statements)

References 37 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there has been increasing use of herbal drugs in LC treatment, their system-level anticancer mechanisms have not been comprehensively understood. Here, we employed a network pharmacological approach to uncover the therapeutic mechanisms of FDY2004 [ 9 ] in LC treatment from a system-level view. The network pharmacological investigation of FDY2004 revealed 29 active chemical components that interact with 141 lung cancer-associated therapeutic targets, mediating the anti-LC effects of the herbal drug.…”

Section: Discussionmentioning

confidence: 99%

“…FDY2004 is a herbal drug composed of three herbal medicines, namely, Moutan Radicis Cortex (MRC), Persicae Semen (PS), and Rhei Radix et Rhizoma (RRR) (Supplementary Table S1 ) [ 9 ]. This herbal drug may exert potent antiproliferative effect against LC cells (Supplementary Table S1 ) [ 9 ]; however, its system-level anticancer mechanisms in LC treatment remain to be elucidated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Uncovering the Anti-Lung-Cancer Mechanisms of the Herbal Drug FDY2004 by Network Pharmacology

Lee¹,

Kang

Park³

et al. 2021

Evidence-Based Complementary and Alternative Medicine

Self Cite

View full text Add to dashboard Cite

With growing evidence on the therapeutic efficacy and safety of herbal drugs, there has been a substantial increase in their application in the lung cancer treatment. Meanwhile, their action mechanisms at the system level have not been comprehensively uncovered. To this end, we employed a network pharmacology methodology to elucidate the systematic action mechanisms of FDY2004, an anticancer herbal drug composed of Moutan Radicis Cortex, Persicae Semen, and Rhei Radix et Rhizoma, in lung cancer treatment. By evaluating the pharmacokinetic properties of the chemical compounds present in FDY2004 using herbal medicine-associated databases, we identified its 29 active chemical components interacting with 141 lung cancer-associated therapeutic targets in humans. The functional enrichment analysis of the lung cancer-related targets of FDY2004 revealed the enriched Gene Ontology terms, involving the regulation of cell proliferation and growth, cell survival and death, and oxidative stress responses. Moreover, we identified key FDY2004-targeted oncogenic and tumor-suppressive pathways associated with lung cancer, including the phosphatidylinositol 3-kinase-Akt, mitogen-activated protein kinase, tumor necrosis factor, Ras, focal adhesion, and hypoxia-inducible factor-1 signaling pathways. Overall, our study provides novel evidence and basis for research on the comprehensive anticancer mechanisms of herbal medicines in lung cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Uncovering the Anti-Lung-Cancer Mechanisms of the Herbal Drug FDY2004 by Network Pharmacology

Lee¹,

Kang

Park³

et al. 2021

Evidence-Based Complementary and Alternative Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…[10][11][12] Results from clinical studies indicate that the combinatorial use of herbal drugs and chemotherapy can increase the tumor response, improve the quality of life, alleviate toxic events, and prolong the survival of cancer patients when compared with the case of using chemotherapy alone. 13,14 FDY2004 is an herbal decoction prepared from three herbal medicines, 15 Moutan Radicis Cortex (MRC), Persicae Semen (PS), and Rhei Radix et Rhizoma (RRR), which possess potent anticancer properties against different cancer types, including BC. [16][17][18][19] Although FDY2004 is known to exert antiproliferative and antioxidant effects in BC cells, 15 the pharmacological mechanisms of its anticancer activity against BC have not been investigated from a systemic perspective.…”

Section: Introductionmentioning

confidence: 99%

“…13,14 FDY2004 is an herbal decoction prepared from three herbal medicines, 15 Moutan Radicis Cortex (MRC), Persicae Semen (PS), and Rhei Radix et Rhizoma (RRR), which possess potent anticancer properties against different cancer types, including BC. [16][17][18][19] Although FDY2004 is known to exert antiproliferative and antioxidant effects in BC cells, 15 the pharmacological mechanisms of its anticancer activity against BC have not been investigated from a systemic perspective.…”

Section: Introductionmentioning

confidence: 99%

A Network Pharmacology Analysis of the Systems-Perspective Anticancer Mechanisms of the Herbal Drug FDY2004 for Breast Cancer

Lee¹,

Kang

Park³

et al. 2021

Natural Product Communications

Self Cite

View full text Add to dashboard Cite

Breast cancer is a malignant tumor with high incidence, prevalence, and mortality rates in women. In recent years, herbal drugs have been assessed as anticancer therapy against breast cancer, owing to their promising therapeutic effects and reduced toxicity. However, their pharmacological mechanisms have not been fully explored at the systemic level. Here, we conducted a network pharmacology analysis of the systems-perspective molecular mechanisms of FDY2004, an anticancer herbal formula that consists of Moutan Radicis Cortex, Persicae Semen , and Rhei Radix et Rhizoma, against breast cancer. We determined that FDY2004 may contain 28 active compounds that exert pharmacological effects by targeting 113 breast cancer-related human genes/proteins. Based on the gene ontology terms, the FDY2004 targets were involved in modulating biological processes such as cell growth, cell proliferation, and apoptosis. Pathway enrichment analysis identified various breast cancer-associated pathways that may mediate the anticancer activity of FDY2004, including the PI3K-Akt, MAPK, TNF, HIF-1, focal adhesion, estrogen, ErbB, NF-kappa B, p53, and VEGF signaling pathways. Thus, our analysis offers novel insights into the anticancer properties of herbal drugs for breast cancer treatment from a systemic perspective.

show abstract

“…FDY2004 is an herbal drug consisting of Moutan Radicis Cortex (MRC), Persicae Semen (PS) , and Rhei Radix et Rhizoma (RRR). 12 This herbal agent has demonstrated potent anticancer properties in breast and lung cancer cells. 12 However, its pharmacological activity against CC has not been examined.…”

mentioning

confidence: 99%

A Comprehensive Understanding of the Anticancer Mechanisms of FDY2004 Against Cervical Cancer Based on Network Pharmacology

Lee¹,

Kang²,

Park³

et al. 2021

Natural Product Communications

Self Cite

View full text Add to dashboard Cite

Herbal drugs are continuously being developed and used as effective therapeutics for various cancers, such as cervical cancer (CC); however, their mechanisms of action at a systemic level have not been explored fully. To study such mechanisms, we conducted a network pharmacological investigation of the anti-CC mechanisms of FDY2004, an herbal drug consisting of Moutan Radicis Cortex, Persicae Semen , and Rhei Radix et Rhizoma. We found that FDY2004 inhibited the viability of human CC cells. By performing pharmacokinetic evaluation and network analysis of the phytochemical components of FDY2004, we identified 29 bioactive components and their 116 CC-associated pharmacological targets. Gene ontology enrichment analysis showed that the modulation of cellular functions, such as apoptosis, growth, proliferation, and survival, might be mediated through the FDY2004 targets. The therapeutic targets were also key components of CC-associated oncogenic and tumor-suppressive pathways, including PI3K-Akt, human papillomavirus infection, IL-17, MAPK, TNF, focal adhesion, and viral carcinogenesis pathways. In conclusion, our data present a comprehensive insight for the mechanisms of the anti-CC properties of FDY2004.

show abstract

Influence of Decoction Duration of FDY2004 on Its Physicochemical Components and Antioxidant and Antiproliferative Activities

Cited by 6 publications

References 37 publications

Uncovering the Anti-Lung-Cancer Mechanisms of the Herbal Drug FDY2004 by Network Pharmacology

Uncovering the Anti-Lung-Cancer Mechanisms of the Herbal Drug FDY2004 by Network Pharmacology

A Network Pharmacology Analysis of the Systems-Perspective Anticancer Mechanisms of the Herbal Drug FDY2004 for Breast Cancer

A Comprehensive Understanding of the Anticancer Mechanisms of FDY2004 Against Cervical Cancer Based on Network Pharmacology

Contact Info

Product

Resources

About